PARP Inhibitor–Based Combinations to Improve Patient Outcomes in Prostate Cancer: An Evidence-Based Global Perspective

Download this slideset for expert insight on the latest evidence on PARP inhibition and novel PARP inhibitor combination therapy in advanced prostate cancer.
Charles J. Ryan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.99 MB
Released: April 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 5, 2022

Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).

Katy E. Beckermann, MD, PhD Released: June 5, 2022

Downloadable slideset from Naomi B. Haas, MD on adjuvant approaches and first line treatment options for patients with RCC, from Clinical Care Options (CCO).

person default Naomi B. Haas, MD Released: June 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings